This site has been optimized to work with modern browsers and does not fully support your version of Internet Explorer.

Life Sciences Industrial Strategy

OAHP is making unique contributions in the following areas specifically identified by the Life Sciences Industrial Strategy updated in January 2020.

The report follows on from the life sciences industrial strategy, written by the Government’s Life Science’s Champion Professor Sir John Bell. It sets out the progress in delivering the vision of the strategy since it was published in 2017.

The report is organised into five key themes:

  • NHS collaboration
  • business environment
  • reinforcing the UK science offer, including clinical research, data and genomics
  • skills
  • advanced therapies, including developing advanced therapies and advanced therapies manufacturing

OAHP is particularly focused in the following areas:

Genomics: OAHP led in the development of polygenic risk scores (Donnelly), the scientific support for WGS analysis of UK Biobank, and used GEL data to deliver the largest number of defined variants. OAHP has relationships with Amgen, J&J, GSK and AZ in genomics.

Data: OAHP leads the Digital Trials Platform and contributes to AI advances in imaging and digital pathology. Nationally, UoO has developed approaches to the creation of metadata catalogues that have led work in the NIHR HIC and with NHS Digital. OAHP will also lead work on the ethics, social and policy aspects of AI and digital healthcare.

OAHP will:

  • Support early stage companies locally and promote growth. OAHP has the UK’s leading rate and portfolio of spin out companies (~20/year).
  • Develop strategic partnerships across the Oxford-Cambridge Knowledge Arc, including Cambridge University Health Partners, expanding current collaborations, supporting commercial and economic developments and deliver innovations into healthcare.
  • Build on commercial relationships e.g. with Novo Nordisk to address the challenge of diabetes and chronic disease; build on investments in Big Data including collaborations with Novartis, J&J, Sensyne Health and Bayer; partnering with MSD, J&J and GE Healthcare; with Imperial and LSHTM
  • create a £67m Vaccines Manufacturing Innovation Centre at Harwell to accelerate early stage clinical development, and provide emergency response capability for the UK Government.
  • Support local education and training programmes to build workforce skills that support adoption of new technologies, with dissemination of best practice to expand national capabilities.

OAHP expertise in pragmatic trials include the ProtecT trial (early detection and treatment for localised prostate cancer and the DROPLET study (total diet replacement for treatment of obesity in primary care). OAHP developed innovative pragmatic trial designs for digital interventions, e.g. the i4i-funded game Change trial of automated virtual reality (VR) cognitive therapy in psychosis and the OASIS trial of the Sleepio app in mental health, improving sleep, wellbeing, and quality of life, in line with the NHS Long Term Plan.

OAHP will leverage its primary care research (one of the largest and highly ranked centres globally), to deliver trials that will change international guidelines and practice. This follows the examples of stroke prevention in atrial fibrillation (BAFTA, SAFE, and SMART trials), heart failure (ECHOES and REFER trials), and hypertension self management (TASMINH series).

The work to support the LSIS is shown below

The graphic provides examples of how work in Oxford links across the UK and looks to support key initiatives in the Life Sciences